Immobilized TROP2 His Tag Protein, Human (Cat. No. UA010224) at 2.0μg/ml (100μl/well) can bind Anti-TACSTD2/TROP2/EGP1 Monoclonal Antibody (Sacituzumab) (Cat. No. UA016060) with EC50 of 0.40-0.60 ng/ml.
Anti-TACSTD2/TROP2/EGP1 Monoclonal Antibody (Sacituzumab)
Anti-TACSTD2/TROP2/EGP1 Monoclonal Antibody (Sacituzumab)
Price:
Regular price
$285 USD
Regular price
Sale price
$285 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Human |
| Antigen | TACSTD2/TROP2/EGP1 |
| Antibody Type | Human mAb |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Endotoxin | <1EU/mg |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, containing no preservative |
| Stability & Storage | 2 to 8 °C for 2 weeks under sterile conditions; |
Background
TACSTD2 (Trophoblast Cell Surface Antigen 2, also known as TROP2 or EGP1) is a type I transmembrane glycoprotein belonging to the GA733 gene family, originally identified on the surface of human placental trophoblast cells. Functionally, it serves as a calcium signal transducer that regulates cell proliferation, differentiation, and apoptosis through downstream pathways including MAPK and PI3K/AKT, while also participating in embryonic development and tumorigenesis. Clinically, TACSTD2 is highly expressed in various solid tumors, including triple-negative breast cancer, urothelial carcinoma, and lung cancer, and is associated with tumor invasion, metastasis, and poor prognosis. The antibody-drug conjugate Sacituzumab Govitecan (SG), developed against this target, delivers the topoisomerase I inhibitor SN-38 specifically to tumor cells and has demonstrated significant survival benefits in multiple phase III clinical trials for metastatic triple-negative breast cancer, HR+/HER2- breast cancer, and urothelial carcinoma, representing a major breakthrough in pan-cancer therapeutics.
Picture
Picture
ELISA
